The concentration of tissue plasminogen activator and urokinase in plasma and tissues of patients with ovarian and uterine tumors

Saito, Kaoru; Nagashima, Makoto; Iwata, Masanori; Hamada, Hiroki; Sumiyoshi, Kenichi; Takada, Yumiko; Takada, Akikazu

doi:10.1016/0049-3848(90)90207-s

Cited by 39 publications

(20 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This agrees with previous results on endometrial cancer (Camiolo et al, 1987;Gleeson et al, 1991;Niklasson et al, 1981;Saito et al, 1990;Soszka and Olszewski, 1986;Svanberg and Åstedt, 1979) and with the general perception of u-PA as being a crucial enzyme initiating extracellular proteolysis during tumor progression (Danø et al, 1994). However, since the proportion of epithelial to stromal cells is increased in cancer compared to normal endometria and normal epithelial cells release 3 to 4 times more u-PA than stromal cells in vitro (Casslén et al, 1992), the increased fraction of epithelial cells may be partly responsible for the increased content of u-PA in cancer tissues.…”

Section: Discussionsupporting

confidence: 83%

“…The tissue content of t-PA is reportedly not increased in a number of malignant as compared to corresponding benign tumors, but, it is markedly increased in the peritoneal ascitic fluid of patients with ovarian cancer (Casslén et al, 1994). Endometrial cancer tissue concentrations of t-PA are equal to or lower than those of normal endometrial tissue (Gleeson et al, 1991;Saito et al, 1990). In fact, the tissue content of t-PA is inversly related to malignancy in breast, ovarian and esophageal cancer (Duffy et al, 1988;Hewin et al, 1996;Pujade-Lauraine et al, 1993).…”

mentioning

confidence: 94%

“…It has been reported that endometrial carcinomas release high amounts of PA activity, mainly u-PA, in tissue culture (Camiolo et al, 1987;Svanberg and Åstedt, 1979). u-PA is also increased in uterine washings (Niklasson et al, 1981), tissue homogenates (Gleeson et al, 1991;Saito et al, 1990;Soszka and Olszewski, 1986) and peripheral blood (Koelbl et al, 1988) of patients with endometrial carcinoma.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Discordant expression of mRNA and protein for urokinase and tissue plasminogen activators (u-PA, t-PA) in endometrial carcinoma

et al. 1998

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 83%

mentioning

confidence: 94%

mentioning

confidence: 99%

See 1 more Smart Citation

Discordant expression of mRNA and protein for urokinase and tissue plasminogen activators (u-PA, t-PA) in endometrial carcinoma

et al. 1998

View full text Add to dashboard Cite

“…However, we can consider that the tumour cells are the major producer. Saito et al (1990) have shown that the plasmatic concentration of uPA did not vary between patients with ovarian or uterine benign and malignant tumours. By immunohistochemistry, Janicke et al (1990) and Costantini et al (1991) have found uPA in the cytoplasma and the plasma membrane of breast tumour cells.…”

Section: Patientsmentioning

confidence: 99%

“…uPA, Cath D and PAIs have been found in plasma (Saito et al, 1990;Freiss et al, 1988;Kruithof et al, 1987), and in many types of normal cells (Bernik et al, 1981;Jaffe, 1987;Chapman et al, 1982;Bergman et al, 1986;Keski-Oja et al, 1988;Wilson et al, 1987;Tissot et al, 1984;Wohlwend et al, 1987). However, we can consider that the tumour cells are the major producer.…”

Section: Patientsmentioning

confidence: 99%

Relationship between cathepsin D, urokinase, and plasminogen activator inhibitors in malignant vs benign breast tumours

Foucre

Bouchet²,

Hacène³

et al. 1991

Br J Cancer

View full text Add to dashboard Cite

Summary The concentrations of cathepsin D (Cath D), urokinase (uPA) and two plasminogen activator inhibitors (PAI-I and PAI-2) were analysed in the cytosols of 130 human mammary tumours (43 benign tumours and 87 primary and unilateral breast carcinomas). uPA, PAI-i and PAI-2 levels were measured by antigenic immunoassays and Cath D by immunoradiometric assay. The median levels of the four parameters were significantly higher in the malignant tumours than in the benign ones. Cath D and uPA increases were 4-fold and 5-fold respectively. PAI-I and PAI-2 increases were much more important, 74-fold and 29-fold respectively. In malignant tumours, median levels of Cath D and uPA did not vary according to classical prognostic factors (histologic grade, presence or absence of axillary lymph nodes, steroid receptors, UICC stage, tumour size, age, and menopausal status). However, PAI-I decreased in ER+ and PR+ tumours and PAI-2 increased in menopausal women's tumours. When Cath D, uPA, PAI-I and PAI-2 levels in malignant tumours were compared, positive correlations were found for all combinations. The implication of plasminogen activator inhibitors in the phenomenon was surprising and merits further investigation using tools other than global antigen measurements in tumours.

show abstract

Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination

Nagayama

Sato

Hayakawa

et al. 1994

Cancer

View full text Add to dashboard Cite

Background. Evidence suggests that plasminogen activators and their inhibitors play an important role in tumor spread. Methods. In this study, we measured the antigen levels of urokinase (u‐PA), tissue plasminogen activator (t‐PA), type 1 plasminogen activator inhibitor (PAI‐1), and type 2 plasminogen activator inhibitor (PAI‐2) in lung cancer tissue (19 adenocarcinomas and 19 squamous cell carcinomas) and normal lung tissue. Results. u‐PA, PAI‐1, and PAI‐2 antigen levels in cancer tissue were significantly higher than those in normal tissue (P < 0.001 in u‐PA and PAI‐1; P < 0.005 in PAI‐2), whereas t‐PA antigen levels in cancer tissue were significantly lower than those in normal tissue (P < 0.005). In cases with lymph node involvement (LN+ cases), PAI‐2 antigen levels were significantly lower than those in cases without lymph node involvement (LN− cases) (P < 0.02), whereas there was no difference in either u‐PA or PAI‐1 antigen levels between these two groups. Furthermore, u‐PA antigen levels showed a significant positive correlation with PAI‐2 antigen levels in LN− cases (r = 0.696; P < 0.005), although there was no correlation between these two parameters in LN+ cases. Conclusions. The antigen levels of u‐PA, PAI‐1, and PAI‐2 in cancer tissue were significantly higher than those in normal tissue, and lower content of PAI‐2 was associated with lymph node metastasis. Cancer 1994; 73:1398–405.

show abstract

The concentration of tissue plasminogen activator and urokinase in plasma and tissues of patients with ovarian and uterine tumors

Cited by 39 publications

References 12 publications

Discordant expression of mRNA and protein for urokinase and tissue plasminogen activators (u-PA, t-PA) in endometrial carcinoma

Discordant expression of mRNA and protein for urokinase and tissue plasminogen activators (u-PA, t-PA) in endometrial carcinoma

Relationship between cathepsin D, urokinase, and plasminogen activator inhibitors in malignant vs benign breast tumours

Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination

Contact Info

Product

Resources

About